‘Michael’ Rocks Box Office With Record-Setting $97 Million Debut

"Michael" opened with $97 million domestically and $217 million globally, marking the best-ever biopic debut and far exceeding the $50 million to $60 million tracking range. The film’s strong audience reception (CinemaScore A-) offsets weak reviews, and its $200 million budget means it needs substantial global box office to pay off, though Lionsgate now has a major hit on its hands. Imax contributed $13.8 million domestically and $24.5 million globally, underscoring strong premium-format demand.

Analysis

The key trade-through here is not just a single-film box-office win, but a stronger-than-expected monetization signal for premium-format theatrical exhibition. When a tentpole biopic over-indexes in IMAX and other large formats, it validates pricing power, higher occupancy per screen, and a wider moat versus standard seating — a favorable mix shift for premium exhibitors and format licensors even if the underlying film studio economics are messy. That matters because the market tends to underwrite box office as an ad hoc event; the second-order effect is that studios may lean harder into eventization for non-franchise IP, which supports a longer runway of premium-format demand.

For IMAX specifically, the setup is better than a one-weekend pop: musical biopics have shown repeatability when they pair audience familiarity with spectacle, and the premium-format contribution suggests the share of box office that is incremental rather than merely cannibalized. The more important signal is that audience scores are decoupled from critic scores, which usually translates into a longer theatrical tail and better international legs than the opening-week estimates imply. If that tail holds, consensus may be underestimating FY revenue contribution from both box-office participation and system installation/upgrade cadence tied to exhibitor confidence.

The main risk is sentiment mean-reversion if controversy overwhelms the narrative on the next news cycle, or if the film front-loads demand and collapses after the initial fan base is exhausted. That said, the time horizon for the trade is months, not days: the market can re-rate on a combination of sustained hold rates, Imax share persistence, and a string of comparable premium-format hits. The contrarian angle is that the studio recipient economics may be less interesting than the exhibitor economics — the market may be too focused on headline gross and not enough on the higher-margin format mix that accrues to IMAX.

Key Decisions for Investors

• Long IMAX into the next 4-8 weeks on film-hold-rate confirmation; risk/reward favors a continued re-rating if premium-format share stays above ~10-12% globally and domestic weekends decline more slowly than the broader box office.
• Pair trade: long IMAX / short a basket of studio-heavy media names with weaker IP monetization visibility; thesis is that premium-format scarcity captures more durable economics than one-off production upside.
• Sell downside puts on IMAX with 1-2 month tenor if implied volatility stays elevated; the near-term tail risk is mostly sentiment-driven, while the upside comes from multiple weeks of box-office tail data.
• If weakness develops after the opening surge, add on a 10-15% pullback rather than chasing strength; the risk/reward improves if the market overreacts to any single weekend decay print.